Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by deCou, J. M.
Right arrow Articles by Fontanesi, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by deCou, J. M.
Right arrow Articles by Fontanesi, J.

Annals of Surgical Oncology, Vol 2, Issue 6 524-529, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience

J. M. deCou, B. N. Rao, D. M. Parham, T. E. Lobe, L. Bowman, A. S. Pappo and J. Fontanesi
Department of Surgery, St. Jude Children's Research Hospital, TN 38101, USA.

BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon in young patients. To contribute to the understanding of these tumors, we reviewed the records of all patients treated for PNSTs at one institution over a 30-year period. METHODS: We reviewed the records of eight patients treated for benign PNSTs and 28 patients treated for 29 MPNSTs. We focused on the latter group, statistically testing several clinical factors for their significance in affecting survival. RESULTS: Five-year survival in patients with MPNSTs was 39%. The most significant prognostic factor was gross tumor resectability (p = 0.0004). Five-year survival for patients with resectable tumors was 65%, whereas no patient with unresectable disease survived > 25 months. Tumor grade, site, and patient race were also significant factors by univariate analysis but were not significant when adjusted for resectability. CONCLUSION: Gross tumor resection is crucial in treating malignant PNSTs. Supplemental radiation therapy is recommended for positive microscopic margins. More effective treatment is still being sought for unresectable disease.


This article has been cited by other articles:


Home page
 JCOHome page
M. Carli, A. Ferrari, A. Mattke, I. Zanetti, M. Casanova, G. Bisogno, G. Cecchetto, R. Alaggio, L. De Sio, E. Koscielniak, et al.
Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group
J. Clin. Oncol., November 20, 2005; 23(33): 8422 - 8430.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. B. Pratt, A. S. Pappo, P. Gieser, J. J. Jenkins, J. Neff, B. Rao, D. Green, P. Thomas, R. Marcus, D. Parham, et al.
Role of Adjuvant Chemotherapy in the Treatment of Surgically Resected Pediatric Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study
J. Clin. Oncol., April 1, 1999; 17(4): 1219 - 1219.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.